Zitgard Gel is a topical formulation containing Clindamycin 1% w/w and Nicotinamide 4% w/w, indicated for the treatment of inflammatory acne vulgaris. Clindamycin, a lincosamide antibiotic, exerts its therapeutic effect by inhibiting bacterial protein synthesis, thereby reducing the proliferation of Propionibacterium acnes, a key pathogen implicated in acne pathogenesis. Nicotinamide, a form of vitamin B3, possesses anti-inflammatory and sebum-regulating properties, contributing to the reduction of erythema and lesion severity. The combination of these active ingredients offers a dual mechanism of action, targeting both microbial colonization and inflammatory processes. Zitgard Gel is applied topically to the affected areas once or twice daily as directed by a healthcare professional. It is generally well tolerated; however, mild local adverse effects such as dryness, erythema, or peeling may occur. Patients should avoid contact with eyes, mucous membranes, and broken skin. The use of Zitgard Gel is contraindicated in individuals with known hypersensitivity to clindamycin, nicotinamide, or any component of the formulation. Caution is advised in pregnant or lactating women, and use should be under medical supervision. Consistent application as prescribed is essential for optimal therapeutic outcomes in acne management.